Welcome to PharOS
Developing Value
Supplying Success
PharOS is a privately owned pharmaceutical company, developing, manufacturing and supplying generics and value added products with a global portfolio of more than 113 products and over 10.308 marketing authorizations worldwide.
1 3
Expertise
First to market
Last to Exit
PharOS is a multi-disciplinary organization, in recognition of the numerous different knowledge sets that are required for a proper pharmaceutical product development, registration and supply. Our expertise covers all aspects of product development from API sourcing up to market release.
2 3
The team
Our core competitive
advantage
At PharOS, we have a highly skilled workforce of more than 413 professionals all focused on developing and placing in the market top quality generic and other value added pharmaceuticals that improve the lives of patients to more than 119 countries.
3 3
113
PRODUCTS
DEVELOPED/UNDER DEVELOPMENT
64
PRODUCTS LAUNCHED
103
Marketing Authorizations
Worldwide
119
COUNTRY
PRESENCE
OUR MISSION
FIRST TO LAUNCH, LAST TO EXIT
Our mission in PharOS is to materialize in the most efficient way our customers’ trust, by ensuring that their products will be among the first to be launched after patent expiry and the last ones to exit the market.
ABOUT PHAROS
TIMELINE
VIEW OUR STORY
FORCES UNITED
THE TEAM
OUR
WORLDWIDE
PRESENCE
MORE THAN 119 COUNTRIES
10308+ MARKETING AUTHORIZATIONS
MORE THAN 490 CLIENTS
image/svg+xml
Registered/Under RegistrationLaunched
PRODUCTS
Today’s ideas...Tomorrow’s opportunities...
We provide affordable, high-quality medicines to more than 119 countries worldwide
VIEW ALL PRODUCTS
LATEST NEWS
Today’s ideas...Tomorrow’s opportunities...
Our mission in PharOS is to materialize in the most efficient way our customers trust, by ensuring that their products will be among the first to be launched after patent expiry and the last ones to exit the market.

WORLD 𝗪ATER 𝗗AY 𝟮𝟬𝟮𝟲

💧 On 𝗪𝗼𝗿𝗹𝗱 𝗪𝗮𝘁𝗲𝗿 𝗗𝗮𝘆 𝟮𝟬𝟮𝟲, water stands at the intersection of human rights, equity, and resilience. Access remains uneven, shaping lives in profoundly different ways.
READ MORE